title: Dendritic cell-based immunotherapy for prostate cancer.
abstract: Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.
authors.affiliation: Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WA, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Tjoa
authors.forename: P A
authors.initials: PA
authors.lastname: Lodge
authors.forename: M L
authors.initials: ML
authors.lastname: Salgaller
authors.forename: A L
authors.initials: AL
authors.lastname: Boynton
authors.forename: G P
authors.initials: GP
authors.lastname: Murphy
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines